There has been an increasing concern about the changing incidence patterns of some types of cancers including age at diagnosis. While there is at least some evidence that some cancers currently occur at age earlier than that expected based on historical data, we still lack evidence about age trends in most types of cancers. This study aims to explore current age distributions for different types of malignancies in the United States based on data from SEER.
Data were obtained using SEER*Stat version 8.3.5, where (SEER 18 Regs Nov 2017 Submission) database was used as the data source. Only cases diagnosed between 1996-2015 with malignant behavior, known age, and microscopic confirmation were included. Data were exported using the case listing session and were analyzed using SPSS version 21.
Median age at diagnosis was significantly higher in the period between 2006-2015 than in the period 1996-2005 for most types of cancers. GIT malignancies and CML, however, showed an exception with a significantly younger median age of diagnosis. The table shows age distribution as well as median age for some common types of cancers including comparison between cases in the 1996-2005 and 2006-2015 time periods.Table: 1582P
|Median Age (in years)||Number and Percentage of Cases in Different Age Groups (1996-2015)|
|< 18 years||18-35 years||ears||> 55 years|
|Breast Cancer||61||61||62 *||11||.0%||23824||2.3%||340441||33.4%||655907||64.3%|
|Cervical and Uterine Cancer||60||59||60 *||22||.0%||13937||5.7%||77435||31.9%||151283||62.3%|
|Colorectal Cancer||69||71 *||67||338||.0%||10166||1.5%||133171||19.2%||550771||79.3%|
|Stomach Cancer||70||71 *||69||36||.0%||1952||1.8%||18304||17.3%||85274||80.8%|
|Liver Cancer||64||65 *||63||208||.2%||1100||1.0%||23862||22.0%||83175||76.8%|
|Pancreatic Cancer||70||71 *||69||58||.0%||998||.6%||22136||14.1%||134330||85.3%|
Significantly higher median age.
Except for GIT malignancies and CML, cancer is still being diagnosed at higher median age. With few exceptions, patients who are over 55 years old are still constituting the vast majority of cases.
Clinical trial identification
Legal entity responsible for the study
Mohamed Alaa Gouda.
Has not received any funding.
The author has declared no conflicts of interest.